Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

CADD522 shows promise against osteoporosis

Analysis based on 8 articles · First reported Sep 07, 2026 · Last updated Sep 08, 2026

Sentiment
40
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The findings could stimulate interest in CADD522 as a potential osteoporosis treatment, potentially benefiting the developers and investors in the pharmaceutical sector. However, as the drug is in early preclinical stages, significant time and investment are needed before any market impact materializes.

Pharmaceuticals Biotechnology Healthcare

Researchers at the University of East Anglia, collaborating with the University of Maryland, College Park, the International Rice Research Institute, and the University of Stirling, published a peer-reviewed experimental study in npj Drug Discovery showing that CADD522, a drug originally developed as a cancer treatment, improved bone health and reduced body fat in post-menopausal mice. The drug, a RUNX2 inhibitor, increased bone volume and preserved bone microarchitecture, while also reducing weight and fat deposits in bone marrow. Safety testing in mice, rats, and dogs showed the drug was orally bioavailable and well tolerated. The research is at an early animal-testing stage, and the team hopes the benefits will translate to humans.

per
Lead researcher; his reputation and career benefit from the promising findings.
Importance 90.0 Sentiment 60.0
ngo
Collaborating institution; contributes to research and shares in potential benefits.
Importance 40.0 Sentiment 40.0
oth
Collaborating institution; involved in the research, gaining academic recognition.
Importance 40.0 Sentiment 40.0
ngo
Funded safety testing; supports drug development, potentially benefiting from successful outcomes.
Importance 30.0 Sentiment 30.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.